Androgen deprivation therapy is a common treatment for advanced or metastatic prostate cancer. Like the normal prostate, most tumors depend on androgens for proliferation and survival but often develop treatment resistance. Hormonal treatment causes many undesirable side effects which significantly decrease the quality of life for patients. Intermittently applying androgen deprivation in cycles reduces the total duration with these negative effects and may reduce selective pressure for resistance. We extend an existing model which used measurements of patient testosterone levels to accurately fit measured serum prostate specific antigen (PSA) levels. We test the model's predictive accuracy, using only a subset of the data to find parameter values. The results are compared with those of an existing piecewise linear model which does not use testosterone as an input. Since actual treatment protocol is to re-apply therapy when PSA levels recover beyond some threshold value, we develop a second method for predicting the PSA levels. Based on a small set of data from seven patients, our results showed that the piecewise linear model produced slightly more accurate results while the two predictive methods are comparable. This suggests that a simpler model may be more beneficial for a predictive use compared to a more biologically insightful model, although further research is needed in this field prior to implementing mathematical models as a predictive method in a clinical setting. Nevertheless, both models are an important step in this direction.
Introduction

Prostate cancer and treatment
The probability of an American man developing prostate cancer in a lifetime is 1 in 6. 28 Although the incidence and death trends for prostate cancer are declining, there is still no curative treatment for patients with distant metastases. 7 Androgen deprivation therapy (ADT) is one of the most common and effective therapies for patients with metastatic cancer 22 and has recently been used to also treat nonmetastatic disease. 4, 17 Although the initial response rate of ADT is above 90%, most patients become resistant to treatment and develop castration-resistant prostate cancer (CRPC). 22 CRPC is usually fatal with a median survival time of 2.5 to 3 years.
22,12
Androgens, specifically testosterone and 5α-dihydrotestosterone (DHT), are essential for maintenance of the prostate. Prostate secretory epithelial cells depend on androgens for proliferation and survival. The testes produce 90-95% of the androgens in the body with the adrenal gland producing the remainder. 7 Androgens regulate cellular proliferation and survival via activation of the androgen receptor (AR), a nuclear hormone receptor. Around 90% of serum testosterone that enters the prostate is enzymatically converted to DHT, which has a greater affinity for AR than that of testosterone. Ligand binding to AR causes a cascade of events that upregulate proliferation, survival, and secretion of prostate specific antigen (PSA). 6 Serum PSA is used as a biomarker for prostate cancer because PSA expression is maintained by cancerous cells. While its effectiveness as a diagnostic tool is controversial, PSA is useful for gauging the response of disease to ADT. ADT inhibits AR signaling by blocking androgen production and AR binding. Therapy induces regression of both mass and PSA secretion by the prostate and cancer.
ADT can be performed by surgical or chemical castration. Orchiectomy, the removal of the testes, is a relatively simple procedure that results in a decrease of testosterone levels. However, chemical castration is more common due to the psychological effects of the surgery. 27, 18 Current chemical castration options include luteinizing hormone release hormone (LHRH) agonists, Gonadotropin releasing hormone (GnRH) antagonists, and anti-androgens. A combination of an anti-androgen and a LHRH agonist is called total androgen blockade. 6, 7 Intermittent androgen deprivation (IAD) therapy consists of alternating periods of on-and off-treatment and provides many benefits over continuous (CAD) therapy, including increased health related quality of life, reduced therapy costs (LHRH agonists cost about $300 to $400 a month 17 ), and potentially delaying resistance to treatment, although the latter remains controversial. 24, 20, 17, 8 ADT causes numerous side effects such as erectile dysfunction, loss of libido, gynecomastia, osteoporosis, and anemia.
9,17 Some of these side effects can potentially lead to more serious conditions, such as diabetes, hypertension, and cardiovascular disease. 9 Two recent studies by Crook et al. 4 and Hussain et al. 12 compared IAD to CAD therapy in patients with prostate cancer. Crook et al. concluded that IAD was noninferior to CAD in terms of survival, but improvements in quality of life were observed in IAD patients. 4 Hussain et al. observed small improvements in quality of life for IAD patients and but their findings in terms of survival were statistically insignificant; they were not able to rule out a greater risk of death from IAD compared to CAD nor rule out significant inferiority of IAD. 12 Crook et al. 
Recent works
While IAD offers several benefits, there are still controversies in how the treatment should be applied, such as who should receive IAD therapy, when to start and stop therapy, and what thresholds should be used for starting and stopping treatment. 17, 26 Mathematical models are important tools for achieving improved therapy and determining the patient-specific answers to some of these controversies. In 2004, Jackson 15,16 used a system of partial differential equations to investigate the mechanisms for CRPC. The model assumed the tumor comprised of two types of cells, androgen-dependent (AD) and androgen-independent (AI), with the latter contributing to the AI tumor relapse and resistance to therapy. The proliferation and death rates of both cell types differed in various androgen environments; during androgen deprivation, the AD proliferation rate decreased and the AD death rate increased while the AI proliferation rate remained constant and the AI death rate decreased. The results agreed with experimental data, capturing the exponential growth pre-treatment, androgen-sensitivity following therapy, and tumor regrowth.
Ideta et al. 13 presented an ordinary differential equation model consisting of AI and AD cell populations in order to compare CAD and IAD with respect to relapses. They also assumed a decrease in AD proliferation rate and increase in AD death rate during androgen deprivation, however they considered three possible net growth rates for AI cells. Their model included mutations from AD to AI cells.
Hirata et al. 11, 10 considered three cell populations: AD, reversible AI, and irreversible AI. The reversible AI cells, possibly created by adaptations, can revert back to AD cells, whereas the irreversible AI cells cannot. Similarly to Idetaet al., the irreversible changes can be due to mutations. The model was fit to clinical data and used to group patients into categories based on the IAD versus CAD and the prevention of relapse: IAD may prevent a relapse, IAD may delay a relapse, and CAD is more effective in delaying a relapse than IAD. In another investigation, the first two and one-half cycles of treatment were used to find individualized parameters and then predict PSA responses to subsequent treatment. This approach was presented as a basis for future methods of individualized cancer treatment.
Portz et al. 23 developed a novel model of ADT by extending mathematical frameworks in ecology to the two-subpopulation models of ADT. 16, 13 The cell quota model, 5 which relates growth to an intracellular nutrient, was used for proliferation of both the AD and AI cell populations. Since AR signaling reflects the intracellular androgen-AR interactions, the "cell quota" was conceived as intracellular androgen concentrations. A significant difference in this model from previous work 13 was that the so-called AI cells were assumed be responsive to androgens and that PSA production was androgen-independent. The bidirectional mutation rates and cell-specific rates of PSA production were also functions of the cell quota. Cells had a constant death rate and also produced PSA at a constant, baseline rate. The model was validated with clinical data 1 and its accuracy compared to that of the Ideta et al. 13 model. The androgen quota model exhibited significantly greater accuracy for each patient data set. Their results supported the idea that ADT models should assume that AI cells maintain sensitivity to androgens, though to a lesser degree than AD cells. The model was also used to predict future hypothetical treatment cycles. However, unlike the method used in Ref. 11, predictive accuracy was not assessed using subsets of the data. While their conclusions provided information about the mechanisms of resistance, their patient specific predictions lack validity.
Methods and findings
A mathematical model that accurately predicts the next cycle of treatment for an individual patient undergoing IAD therapy is an important tool that can potentially be used in a clinical setting. Here, we first extend the model from Portz et al.
23
(Model 1) by adding an androgen-dependent cell death rate. This extended model has been validated with the same clinical data.
21 Different methods (Methods 1, 2) are then implemented for measuring the accuracy of the model's predictions when using an increasing subset of data. Parameters are found for the first treatment cycle, then used to predict the observed response to the second cycle, and so forth. The results are compared to those obtained using the model by Hirata et al.
11
(Model 2) to make predictions of the same data. Finally, both models are used to predict patient response to a hypothetical future treatment cycle. The predictions produced by Model 1 Method 1 were not very accurate. Model 1 Method 2 and Model 2 Method 2 produced more accurate predictions, although the timing of the predictions was often incorrect. Model 2 Method 1 was also more accurate, but often either had incorrect timing or under-predicted the results. Our results suggest that a simpler model may be more beneficial for a predictive use and that further research is needed in this field prior to implementing mathematical models as a predictive method in a clinical setting.
Mathematical Models
Model 1: Extension of model by Portz et al.
We propose the following prostate cancer model, 21 which is an extension of the model by Portz et al. 23 with death rates dependent on cell androgen quotas: 
baseline production
where
CR to CS X 1 , X 2 represent the AD and AI cell populations, respectively. The terms "androgen-dependent" and "androgen-independent" have been used previously in both mathematical models as well as in biological literature.
14,6,15,13,10 However, "androgen-independent" cells are often not completely independent, but have a lower threshold for androgens. Thus, we refer to AD and AI cells as "castration-sensitive" (CS) and "castration-resistant" (CR), respectively, as seen in recent literature. 25, 18, 22, 7 The proliferation rates are given by Droop's model, which is dependent upon some cell quota or limiting nutrient. Here, the cell quota (Q) is intracellular androgen. µ m represents the maximum proliferation rate and q i is the minimum cell quota. Since CR cells are able to proliferate at lower levels of androgen, q 2 < q 1 .
Portz et al. 23 assume the cell death rate is constant for simplicity. Our extension of the model is the incorporation of an androgen-dependent death rate in addition to the constant death rate δ i . d i represents the maximum androgen-dependent death rate. The shape parameters R i and α represent the half saturation level and hill coefficient, respectively, which describe the cell death rate sensitivity to the cell quota level. Whereas Jackson 16, 15 and Ideta et al. 13 assume the AI death rate decreases as the androgen concentration decreases, we assume the death rates increases as the androgen concentration decreases, which is supported by biological results.
6,25
The model also assumes androgen-dependent mutation rates, λ i , to account for switching between the cell populations. c 1 and c 2 represent the maximum switching rates. K i and n represent the half saturation level and hill coefficient, respectively, which describe the cell switching sensitivity to the cell quota level. We interpret these switching rates as both accommodative and adaptive switching.
21
As serum androgen A increases, the cell uptakes more androgen and approaches the maximum. This maximum uptake rate is regulated by the cell quota Q(t), maximum cell quota q m , minimum cell quota q i , and maximum uptake rate v m . v h represents the uptake half saturation level. µ m (Q i − q i ) represents the amount of cell quota used in the cell for growth. The cell quota degrades at rate b.
PSA, P , is produced at both a baseline rate σ 0 and androgen-dependent rate by both cell populations. σ 1,2 represent the maximum androgen dependent PSA productions by the two cell populations. The shape parameters ρ i and m represent the half saturation level and hill coefficient, respectively, which describe the PSA production rate sensitivity to the cell quota level. PSA is cleared from the blood at rate ε. 
Model 2: Model by Hirata et al.
We compare the predictions produced using Model 1 to the predictions produced from a model by Hirata et al. 10, 11 This model considered an AD cell population (x 1 ), a reversible AI cell population (x 2 ), and an irreversible AI cell population (x 3 ), modeled by the following:
for the on-treatment periods and
for the off-treatment periods. The PSA levels P are modeled by the following:
Whereas Model 1 captures the intermittent property using serum androgen levels as an input, Model 2 uses a binary on-or off-treatment input. Following Hirata et al., the parameters were constrained so that the nondiagonal parameters are non-negative, w 
Data and Simulations
Akakura et al. 1 published results from a study with seven patients undergoing intermittent androgen deprivation therapy. Four of the men (patients 1, 2, 3, 5) had stage C cancer, in which the cancer has spread outside the prostate, but not yet to other parts of the body; one man (patient 4) had stage D1 cancer, in which the cancer has only spread to local lymph nodes; two men (patients 6, 7) had stage D2 or metastasized cancer.
2 The data consisted of serum PSA and testosterone levels, obtained at monthly intervals. Patients received goserelin acetate (LHRH agonist) and cyproterone acetate (anti-androgen) until the PSA level reached a normal level and remained in this range for about four months, although this timing varied greatly among the patients. The patient then stayed off therapy until the levels reached about 20 ng/mL. It should be noted that Akakura et al. state that the upper limit of 20 ng/mL was set arbitrarily and also seems to vary among the patients. For more information on the study, see Ref. 1 .
Since we use the PSA data to verify the models, we are able to use the androgen data directly for Model 1. Following Portz et al., 23 we interpolated the data using piecewise cubic hermit splines and an exponential function between the last offtreatment A(t i ) and first on-treatment A(t f ) data points with l = 1:
This equation was also used for the predicted off-treatment PSA growth with l = 100 for Method 2 (Sec. 3.2). After first fitting the free parameters by hand, we used the Nelder-Mead simplex algorithm 19 to find the free parameters that minimized the mean square error (MSE) between the PSA data and model. The fixed parameter values as well as the free parameter ranges for Model 1 and Model 2 can be found in Tables 1 and 2 respectively. In order to test the accuracy of the prediction, we first find the parameters using only 1.5 cycles of data. Using these parameters, we then run the model for another treatment cycle and compute the error between the future model and the remaining, or "future", data. We repeat this process using 2.5 cycles of data and then 3.5 cycles of data when possible.
In order to make future PSA predictions, we must first generate future serum androgen levels. We propose two different methods, described below, for generating these future androgen levels and then apply these methods to Model 2. To compare these methods and models, we compute both the MSE and mean relative error (MRE) ( Table 5 ) as well as plot the results. The figures compare Model 1 and Model 2, each using both prediction methods, to clinical data for both the PSA levels (ng/ML) and the serum androgen levels (nM) where applicable. The right of the vertical dashed line represents the prediction with the "future" data overlaid for comparison.
Prediction method 1: Average function
We implemented the method used by Portz et al. 23 for generating future serum androgen levels, which consists of generating a rectangular function based on the average off-and on-treatment serum androgen values and off-and on-treatment durations. To apply this method to Model 2, we set the on-and off-treatment binary switch to occur after mean durations of on-and off-treatment.
Prediction method 2: Threshold function
During the clinical trial, 1 the treatment resumed once the PSA levels reached the approximate threshold of 20 ng/mL. This implies that the future androgen levels should depend on the future PSA level. In this method, once the mean on-treatment duration occurs, the androgen level increases using Eq. (8) until a PSA threshold is reached and then decays according to Eq. (8) . Similarly, for Model 2, the treatment remained off until the PSA levels reached a threshold and then the model switched to the on-treatment equations.
Results
Portz et al.
23 used all the provided data to predict the following cycle. However, in doing so, they were not able to test the accuracy of their predictions. We first use an extension of their model (Model 1) and their method (Method 1) and determine the accuracy of the predictions. We then repeat the process three more times to compare the predictions produced by the two models each using the two methods. These results are summarized in Table 3 . A description of the patient-specific predictions are found in Table 4 and the patient-specific errors are found in Table 5 . In the following subsections, we discuss the patient 1 predictions and the general results for each model and method. Table 4 . Testable patient-specific prediction summary. Under refers to under-predicts, over refers to over-predicts, and shift refers to a phase-shift. Cycle refers to the number of cycles of data used to make the prediction. 
Model 1 Method 1
The model is extremely accurate when fitting the used data, however the model is not always accurate when predicting the future cycle (Table 5 ). When using 1.5 cycles of data for patient 1 (Fig. 1) , the model under-predicts the PSA levels, only reaching about 6 ng/mL, when in reality the patient's levels reached about 13 ng/mL. In a clinical setting, the model would indicate that the patient could continue off-treatment when in reality the patient resumed treatment. When assuming 2.5 cycles of data, the model over-predicts the PSA levels, reaching about 37 ng/mL, when in reality the patient reached levels around 20 ng/mL before resuming treatment. In this case, the model would suggest the patient resume treatment much sooner, shortening their off-treatment period. With all 3.5 cycles of data, the model again suggests high PSA levels, however we are not able to test the accuracy of the fourth cycle due to a limited amount of data. Similarly for patients 2-4 (Figs. 2,  3, 4) , the predictions are not very accurate in predicting the PSA levels for various reasons (Tables 4, 5 ). Since the data for patients 5-7 ( Fig. 5) consisted of only 1.5 cycles of data, we were not able to test the accuracy of the predictions.
Model 1 Method 2
We repeated the process of predicting the outcomes of patients using Model 1 with Method 2. For patient 1 (Fig. 1) , assuming 1.5 cycles of data, Method 2 much more accurately predicts the maximum PSA level (about 13 ng/mL) compared to Method 1, although it takes more days to reach this maximum compared to the data. This "shift" in the PSA levels explains the high error values (Table 5) . Similarly, when using 2.5 cycles of data, the predicted PSA levels are "shifted" compared to the data and thus begin the fourth cycle early. However, the MSE and MRE values are smaller than with Method 1. When using all 3.5 cycles of data, Method 2 predicts a maximum PSA level similar to that of the previous cycles, which is much smaller than the predicted PSA levels using Method 1. In general, Method 2 more accurately predicts the PSA peak, as expected, but the timing is often incorrect as seen by the "shift" in PSA levels. 
Model 2 Method 1
We repeated the process a third time using Model 2 with Method 1. For patient 1 using 1.5 cycles of data ( Fig. 1) , the model accurately predicts the PSA level outcome with the smallest MSE value, although the PSA levels are shifted slightly (Table 5) . Similarly, when assuming 2.5 cycles of data, the model produces the most accurate prediction, both in MSE and MRE values, even though there is a slight shift. In general, Model 2 Method 1 seems more accurate compared to Model 1, however the reasons for the errors vary among patients between a "shift" in PSA levels and under-predicting the PSA peak (Table 4) .
Model 2 Method 2
Model 2 with Method 2 produced similar results to Model 2 with Method 1. Both predictions increase at the same rate, however the timing for the switch to on-treatment is different, by design of the methods. For patient 1 ( Fig. 1 ) assuming both 1.5 and 2.5 cycles of data, Methods 1 and 2 produce very similar results. When using all 3.5 cycles, Method 2 switches to on-treatment after Method 1, producing a larger maximum PSA value. When using 1.5 cycles, Model 2 produces a higher rate of increase in PSA levels than Model 1. However when assuming 2.5 and 3.5 cycles, Model 1 produces higher rate of increase in PSA levels. In general, similarly to Model 1 Method 2, Model 2 Method 2 predicts the peak PSA values well, but the timing is often incorrect (Tables 3, 4 ).
Discussion
We extend the work of Portz et al. 23 by first modifying the model to be biologically more accurate and testing the accuracy of the predictions. Similarly to Hirata et al., 11, 10 we use a portion of the data to find the best patient specific parameters and then use these parameters to predict the next cycle of treatment. To determine the accuracy of the prediction, we calculate the MSE and MRE values for the predicted cycle, i.e. to the right of the vertical dashed gray line (Table 5) . We then repeat this process in order to compare the accuracy of the predictions produced by the two prostate cancer treatment models using the two different predictive methods. The model by Hirata et al. is a system of piecewise linear ordinary differential equations representing an AD and two AI cell populations. This model is simpler than the extended Portz model; it contains fewer parameters and does not consider the serum androgen levels. In Method 2, the future serum androgen levels are dependent upon the PSA levels and thus prevent the PSA levels from becoming too high and biologically unreasonable. This method also more accurately follows the methods of the clinical study. While Model 1 using the prediction method proposed by Portz et al. (Method 1) is able to fit the used data well, it is not very accurate In a clinical setting, a goal of predicting the next cycle of treatment is, not only to accurately predict the future PSA levels, but to determine whether or not a patient can go off-treatment for another cycle, thus improving their health related quality of life. Ideally once the patient resumes treatment, the PSA levels return back to normal levels and remain there while on-treatment. However, it is possible that the patient has developed resistance to treatment and the PSA levels remain higher than normal. Since doctors cannot know if a patient's PSA levels will return back to normal once treatment is resumed, the doctors must use their best judgment to determine if and when a patient should go off-treatment.
We test our mathematical model to determine if it can predict whether or not a patient can go off-treatment. For the testable predictions, we consider "normal levels" to be the low PSA levels during the last on-treatment period. Model 1 Method 1 was only able to correctly predict a return to normal levels for 3 out of the 5 testable predictions in the amount of time shown. Model 1 Method 2 and Model 2 Method 1 were able to predict this return to normal levels for all of the testable predictions in the time shown. With Method 2, the model was only able to predict the return to normal levels for 4 of the 5 testable predictions. However, for 4 of the 12 predicted cycles, the model had not yet predicted the full cycle in the given time; the model predicted a very slow increase in PSA levels. Thus, Model 1 Method 2 and Model 2 Method 1 were able to correctly predict that the patient could go off-treatment for all the testable predictions compared to the other two models and methods. Therefore Model 1 Method 2 and Model 2 Method 1 might help in a clinical setting.
For the nontestable predictions, we consider a PSA level of 4 ng/mL to be normal.
11 Model 1 Method 1 predicted a return to normal levels in 1 of the 7 nontestable predictions, Model 1 Method 2 predicted this return for 5 of the 7, Model 2 Method 1 predicted this for 6 of the 7, and Model 2 Method 2 predicted this for 1 of the 7. Since we do not have data to compare these predictions to, we do not know if the levels return to normal or not, i.e. if the patient has developed resistance to the treatment or not. From the results above, Model 1 Method 2 and Model 2 Method 1 predict that a majority of the patients do not develop resistance in the
